Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| These positive outcomes were achieved with 10 ml dose, making a single-dose EXPAREL nerve block a very attractive value proposition to the anesthesia and surgical community for knee and foot and ankle surgeries across all sites of care |
| Throughout the balance of the year, we will continue to ensure we are well positioned for the long-term success |
| We are excited about the opportunities that lie ahead for us |
| Lastly, we're confident in our strong and growing intellectual property estate, and we'll continue to vigorously defend our EXPAREL franchise |
| We're on solid financial and operational footing, and we wish Charlie all the best as he prepares for his well-deserved next chapter |
| And this legislation is a real testament to Pacira's leadership |
| As Frank highlighted, underpinning our sharp focus on growth will be a commitment to solid execution and delivering on the expectations that we set by providing guidance we can confidently stand behind |
| As you might imagine, 340B and GPO now provides a good entry point to accessing our product and combined with ASP plus 6 in the outpatient setting for NOPAIN pain, that should be an attractive value proposition for our customers |
| Consequently, I'm even more enthusiastic for Pacira and the patients we serve |
| So we're really excited about it |
| And lastly, we delivered another quarter of significantly positive adjusted EBITDA of $65.4 million |
| And third is, as you may have -- as I have mentioned earlier, we're enhancing and bolstering our commercial capabilities |
| There were a lot of great things that helped to bring the company to where it is today, and it's remarkable that we've been able to treat 14 million patients so far to date |
| We continue to have a thriving EXPAREL franchise that is supported by a strong and growing patent estate that we will continue to vigorously defend |
| EXPAREL recently passed the 14 million patient mark, and we're confident in its potential to grow to blockbuster status |
| Our strong and growing patent estate leaves us confident that our EXPAREL franchise is well protected and positioned to drive significant and durable long-term sales growth |
| As we do this, we'll hold the bar high with respect to resource allocation and strong execution |
| We believe NOPAIN will result in accelerated and sustainable growth beginning in 2025 that will drive EXPAREL to blockbuster status |
| And it's very positive, as I mentioned earlier in my talk |
| The value proposition is clear as a recent review of 5-year real-world Medicare claims data for hospital outpatient procedures demonstrated a significant correlation between EXPAREL utilization and improved patient outcomes, including opioid prescription pills, emergency room visits and hospital admissions |
| So let me just say this, number one, that as Tony mentioned, we're very confident in where we stand |
| Bottom line, we firmly believe we have built an extensive portfolio of intellectual property around our EXPAREL franchise and it is well protected from multiple directions |
| Importantly, we're going to market with an overwhelmingly positive body of data |
| We have a significant catalyst ahead in NOPAIN, and in 2024, will be a key setup year to ensure we are fit for driving growth in 2025 and beyond |
| Let me just adductor that as we grow, margin will improve accordingly |
| And overall, the year will look better than '23 |
| We always welcome innovation for our patients, and we are pleased to see that the non-opioid space is attracting investments, specifically towards VX-548 as you inquired about |
| And iovera sales improved to $6 million compared to $4.6 million reported in 2022 |
| We currently have the lower extremity launch, which will be a solid tailwind for EXPAREL |
| That said, we're taking several steps to ensure we are fit for growth going forward and best positioned for sustainable success |
| Statement |
|---|
| We know consistently manufacturing EXPAREL would be extremely challenging for a potential generic |
| Financial pressures facing health care systems further incentivize cost-driven approaches |
| The opioid epidemic continues to be a national crisis, underscoring the vital importance of our mission |
| It is important to note that the FDA has established extremely rigorous hurdles for proving bioequivalence to a multivesicular liposomal bupivacaine, and this would have to be accomplished without infringing on the broad Pacira patent state |
| So we expect uptake in these segments to be slower |
| You had asked about optionality regarding the unfavorable rate ruling against us, et cetera |
| as a potential generic would have to successfully litigate and overcome all of our EXPAREL patents |
| Fourth quarter EXPAREL margins were in the high 70% range as expected, but were partially offset by lower margins for ZILRETTA and iovera |
| This first lawsuit alleges patent infringement of EXPAREL U.S |
| For eVenus to be successful in the 495 case, the 348 case as well as any future patent litigation, they will have to overcome every one of our patents |
| And as you know, NOPAIN is really impacting outpatient reimbursement, specifically for CMS patients |
| First, can you talk about some optionality that you have regarding a potential unfavorable ruling regarding the 495 patent in July |
| District Court of New Jersey, alleging infringement of U.S |
Please consider a small donation if you think this website provides you with relevant information